

CITATION REPORT

List of articles citing

Five-year safety and efficacy of belatacept in renal transplant

DOI: 10.1681/asn.2009111109

Journal of the American Society of Nephrology: JASN,
2010, 21, 1587-96.

Source: <https://exaly.com/paper-pdf/48744878/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
167	Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. <i>Transplantation</i> , 2010 , 90, 1528-35	1.8	133
166	An integrated safety profile analysis of belatacept in kidney transplant recipients. <i>Transplantation</i> , 2010 , 90, 1521-7	1.8	97
165	Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation. 2010 , 4, 375-82		6
164	The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. 2011 , 140, 74-80		20
163	Costimulatory pathways in transplantation. 2011 , 23, 293-303		69
162	Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. 2011 , 43, 472-7		21
161	Frontiers in immunosuppression. 2011 , 43, 822-5		5
160	[Perspectives in pediatric renal transplantation]. 2011 , 7, 618-21		1
159	Critical appraisal of belatacept for prophylaxis of rejection in kidney transplant patients. 2011 , 65		
158	Approaching the promise of operational tolerance in clinical transplantation. <i>Transplantation</i> , 2011 , 91, 1065-74	1.8	35
157	Five-Year Safety and Efficacy of Belatacept in Renal Transplantation. 2011 , 2011, 98-99		
156	Immunosuppression and renal transplant rejection: review of current and emerging therapies. 2011 , 1, 859-877		3
155	Belatacept: BENEFIT to the kidney?. <i>American Journal of Transplantation</i> , 2011 , 11, 633; author reply 634	8.7	1
154	Yes There Is Benefit to BENEFIT. <i>American Journal of Transplantation</i> , 2011 , 11, 634-634	8.7	5
153	Clinical applications of biomarkers for acute kidney injury. <i>American Journal of Kidney Diseases</i> , 2011 , 57, 930-40	7.4	32
152	Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. 2011 , 31, 394-407		33
151	Current landscape for T-cell targeting in autoimmunity and transplantation. 2011 , 3, 853-70		45

150	Production and characterization of LEA29Y, a variant of cytotoxic T-lymphocyte antigen 4-immunoglobulin, in <i>Pichia pastoris</i> . 2011 , 91, 543-51		7
149	Belatacept. 2011 , 6, 166-168		
148	Advances in kidney transplant immunosuppression: Emerging biologics. 2011 , 40, 30-32		2
147	New targets for immunosuppression in kidney transplantation: Focus on recent clinical trials. 2011 , 40, 18-22		0
146	Belatacept in renal transplantation. 2011 , 40, 33-36		4
145	Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. 2011 , 7, 103-13		26
144	Novel strategies in immunosuppression: issues in perspective. <i>Transplantation</i> , 2011 , 91, 1057-64	1.8	61
143	Immunosuppression: does one regimen fit all?. <i>Transplantation</i> , 2011 , 92, 251-61	1.8	24
142	Targets of new immunosuppressants in renal transplantation. 2011 , 1, 47-51		
141	Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 430-9	6.9	136
140	An evaluation of sirolimus in renal transplantation. 2012 , 8, 1337-56		23
139	Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation. 2012 , 17, 368-75		9
138	Belatacept: a novel immunosuppressive agent for kidney transplant recipients. <i>Expert Review of Clinical Immunology</i> , 2012 , 8, 719-28	5.1	8
137	Belatacept: A worthy alternative to cyclosporine?. 2012 , 3, 90-2		11
136	Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update. 2012 , 6, 385-93		6
135	Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection. 2012 , 6, 355-62		12
134	Belatacept Post Kidney Transplantation. 2012 , 28, 106-114		
133	Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials. <i>Transplantation</i> , 2012 , 93, 172-81	1.8	30

132	Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function. <i>Transplantation</i> , 2012 , 94, 931-9	1.8	27
131	Kidney transplantation: into the future with belatacept. 2012 , 2, 1171-1176		
130	The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. <i>American Journal of Transplantation</i> , 2012 , 12, 3296-307	8.7	78
129	Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 965-79	5.4	18
128	Current trends in immunosuppressive therapies for renal transplant recipients. 2012 , 69, 1961-75		42
127	Belatacept: a new era of immunosuppression?. <i>Expert Review of Clinical Immunology</i> , 2012 , 8, 527-36	5.1	7
126	CTLA4-Ig. 2012 , 399-406		
125	Belatacept. <i>BioDrugs</i> , 2012 , 26, 413-424	7.9	4
124	Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. 2012 , 21, 2047-61		17
123	CD28 family and chronic rejection: "to belatacept...And beyond!". <i>Journal of Transplantation</i> , 2012 , 2012, 203780	2.3	3
122	Role of regulatory T cells in the promotion of transplant tolerance. 2012 , 18, 761-70		34
121	Belatacept: a new biologic and its role in kidney transplantation. 2012 , 46, 57-67		24
120	Belatacept: from rational design to clinical application. <i>Transplant International</i> , 2012 , 25, 139-50	3	47
119	Abatacept therapy and safety management. 2012 , 79 Suppl 1, 3-84		26
118	Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. <i>American Journal of Transplantation</i> , 2012 , 12, 210-7	8.7	237
117	Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. <i>American Journal of Transplantation</i> , 2012 , 12, 630-9	8.7	194
116	Anemia and erythrocytosis in patients after kidney transplantation. <i>Transplant International</i> , 2012 , 25, 1013-23	3	34
115	Abatacept and Belatacept. 2013 , 283-310		1

114	Calcineurin inhibitors: 40 years later, can we live without. <i>Journal of Immunology</i> , 2013 , 191, 5785-91	5.3	175
113	Infectious complications of immune modulatory agents. 2013 , 15, 465-71		2
112	Immunologic monitoring in kidney transplant recipients. 2013 , 32, 52-61		11
111	New perspectives of immunosuppression. 2013 , 45, 1224-31		8
110	Hypertension after kidney transplantation: a pathophysiologic approach. 2013 , 15, 458-69		22
109	Risk of posttransplant lymphoproliferative disorder associated with use of belatacept. 2013 , 70, 1977-83		27
108	Pathophysiology and treatment options of chronic renal allograft damage. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2438-46	4.3	27
107	Risk evaluation and mitigation strategies: a focus on belatacept. 2013 , 23, 64-70		8
106	Beyond calcineurin inhibitors: emerging agents in kidney transplantation. 2013 , 22, 689-97		11
105	The role of belatacept in transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents. 2013 , 27, E3-11		3
104	Belatacept utilization recommendations: an expert position. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 111-22	4.1	11
103	Costimulation blockade: current perspectives and implications for therapy. <i>Transplantation</i> , 2013 , 95, 527-35	1.8	62
102	Functional Characteristics of C-terminal Lysine to Cysteine Mutant Form of CTLA-4Ig. 2013 , 13, 16-24		2
101	Current Pathways for Immune Manipulation. 2014 , 219-238		
100	Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?. 2014 , 6, 1073-84		17
99	Potential and limitations of regulatory T-cell therapy in solid organ transplantation. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 1197-212	5.1	11
98	Stem cells: Immunology and immunomodulation. 2014 , 53, 122-32		13
97	Belatacept for kidney transplant recipients. 2014 , CD010699		64

96	High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. <i>American Journal of Transplantation</i> , 2014 , 14, 607-14	8.7	44
95	2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. 2014 , 211, 297-311		54
94	Cancer in Renal Transplant Patients. 2014 , 271-286		
93	Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. 2014 , 34, 117-26		24
92	Transplantation: Kidney, Kidney/Pancreas Transplant. 2014 , 175-201		
91	Diabetes and Kidney Disease. 2014 ,		0
90	Targeting co-stimulatory pathways: transplantation and autoimmunity. 2014 , 10, 14-24		108
89	Long-term Outcomes after Islet Transplantation. 2014 , 1314-1333		
88	Candida-elicited murine Th17 cells express high Ctl4 compared with Th1 cells and are resistant to costimulation blockade. <i>Journal of Immunology</i> , 2014 , 192, 2495-504	5.3	25
87	Use of belatacept to maintain adequate early immunosuppression in calcineurin-mediated microangiopathic hemolysis post-renal transplant. 2014 , 18, E140-5		3
86	Maintenance Immunosuppressive Therapy. 2014 , 732-753		
85	Rescue Immunosuppressive Therapy. 2014 , 754-762		
84	Aktueller Stand der immunsuppressiven Therapie unter besonderer Berücksichtigung des transplantierten Patienten in der Chirurgie. 2015 , 9, 232-245		
83	Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation. 2015 , 37, 560-7		19
82	Immunosuppressive minimization with mTOR inhibitors and belatacept. <i>Transplant International</i> , 2015 , 28, 921-7	3	12
81	Immunological risks of minimization strategies. <i>Transplant International</i> , 2015 , 28, 901-10	3	10
80	Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. <i>American Journal of Transplantation</i> , 2015 , 15, 2726-31	8.7	47
79	Does belatacept improve outcomes for kidney transplant recipients? A systematic review. <i>Transplant International</i> , 2015 , 28, 1251-64	3	24

78	Drugs commonly used for kidney transplantation. 2015 , 7, 6-13		
77	Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis. <i>Transplant International</i> , 2015 , 28, 820-7	3	10
76	Hypertension, living kidney donors, and transplantation: where are we today?. 2015 , 22, 154-64		17
75	Biologics in renal transplantation. 2015 , 30, 1087-98		7
74	Haptoglobin enhances cardiac transplant rejection. 2015 , 116, 1670-9		14
73	Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects. 2015 , 75, 1843-52		3
72	Cutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients. <i>Journal of Immunology</i> , 2015 , 195, 4069-73	5.3	49
71	Neurologic Complications After Kidney Transplantation. 2015 , 35, 323-34		6
70	Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. 2015 , 35, 235-54		170
69	Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy. 2016 , 9, 139-50		4
68	Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. 2016 , 11, e0148604		21
67	CD28 Costimulation: From Mechanism to Therapy. <i>Immunity</i> , 2016 , 44, 973-88	32.3	360
66	Immunosuppressive Agents. 2016 , 31-46		2
65	T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation. <i>Transplant Immunology</i> , 2016 , 39, 46-51	1.7	14
64	First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28. <i>Journal of Immunology</i> , 2016 , 197, 4593-4602	5.3	35
63	A safety evaluation of belatacept for the treatment of kidney transplant. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1125-32	4.1	2
62	Should belatacept be the centrepiece of renal transplantation?. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1995-2002	4.3	8
61	Cell-Based Therapy for Degenerative Retinal Disease. <i>Trends in Molecular Medicine</i> , 2016 , 22, 115-134	11.5	107

60	Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 215-27	3.8	6
59	Absence of miR-182 Augments Cardiac Allograft Survival. <i>Transplantation</i> , 2017 , 101, 524-530	1.8	10
58	Rapid Discontinuation of Prednisone in Kidney Transplant Recipients: 15-Year Outcomes From the University of Minnesota. <i>Transplantation</i> , 2017 , 101, 2590-2598	1.8	21
57	Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1001-1012	5.4	18
56	Skin Cancers in Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017 , 17, 2509-2530	8.7	87
55	Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly. <i>American Journal of Transplantation</i> , 2017 , 17, 3219-3227	8.7	22
54	Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. <i>Cellular and Molecular Immunology</i> , 2017 , 14, 146-179	15.4	63
53	Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice. <i>Frontiers in Immunology</i> , 2017 , 8, 1169	8.4	7
52	Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection. <i>JCI Insight</i> , 2017 , 2, e90317	9.9	10
51	Pharmacokinetics and Genomics of Immunosuppressive Drugs. 2017 , 429-443		1
50	No augmentation of indoleamine 2,3-dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients. <i>Clinical and Experimental Immunology</i> , 2018 , 192, 233-241	6.2	3
49	Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate. <i>Transplantation</i> , 2018 , 102, 478-483	1.8	12
48	Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity. <i>Journal of Transplantation</i> , 2018 , 2018, 1968029	2.3	7
47	CTLA4Ig Improves Murine iTreg Induction via TGF and Suppressor Function. <i>Journal of Immunology Research</i> , 2018 , 2018, 2484825	4.5	3
46	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019 , 52, 144-160	3	9
45	Human CTLA4-Ig therapy can give false-positive anti-pig antibody results in primates after xenotransplantation. <i>Transplant Immunology</i> , 2019 , 57, 101243	1.7	2
44	Belatacept in kidney transplantation and its limitations. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 359-367	5.1	18
43	Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019 , 143, 145-194	5.9	13

42	Non-immunological complications following kidney transplantation. <i>F1000Research</i> , 2019 , 8,	3.6	11
41	Impact of selective CD28 blockade on virus-specific immunity to a murine Epstein-Barr virus homolog. <i>American Journal of Transplantation</i> , 2019 , 19, 2199-2209	8.7	1
40	Disease Interception in Autoimmune Diseases: From a Conceptual Framework to Practical Implementation. 2019 , 1-23		
39	Cancer in Dialysis and Transplant Patients. 2019 , 591-607		
38	Interventions to Prevent Nonmelanoma Skin Cancers in Recipients of a Solid Organ Transplant: Systematic Review of Randomized Controlled Trials. <i>Transplantation</i> , 2019 , 103, 1206-1215	1.8	6
37	Pediatric Renal Transplantation. 2019 , 661-675.e7		1
36	Targeting B7-1 in immunotherapy. <i>Medicinal Research Reviews</i> , 2020 , 40, 654-682	14.4	16
35	Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy. <i>Transplant Infectious Disease</i> , 2021 , 23, e13531	2.7	0
34	Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation. <i>Theranostics</i> , 2020 , 10, 8051-8060	12.1	9
33	Primary Care of the Solid Organ Transplant Recipient. 2020 ,		
32	Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation. <i>New England Journal of Medicine</i> , 2020 , 383, 1168-1180	59.2	6
31	Th17 cell inhibition in a costimulation blockade-based regimen for vascularized composite allotransplantation using a nonhuman primate model. <i>Transplant International</i> , 2020 , 33, 1294-1301	3	5
30	Glucose Metabolism After Kidney Transplantation: Insulin Release and Sensitivity With Tacrolimus-Versus Belatacept-Based Immunosuppression. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 462-464	7.4	3
29	Neuroinflammation in Parkinson Disease: Triggers, Mechanisms, and Immunotherapies. <i>Neuroscientist</i> , 2021 , 1073858421991066	7.6	2
28	Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial. <i>American Journal of Transplantation</i> , 2021 , 21, 3066-3076	8.7	0
27	Post-Transplant Cardiovascular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 ,	6.9	3
26	Immunosuppression-related neurological disorders in kidney transplantation. <i>Journal of Nephrology</i> , 2021 , 34, 539-555	4.8	8
25	CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients. <i>JCI Insight</i> , 2017 , 2,	9.9	8

24	Alloresponses of Mixed Lymphocyte Hepatocyte Culture to Immunosuppressive Drugs as an In-Vitro Model of Hepatocyte Transplantation. <i>Annals of Transplantation</i> , 2019 , 24, 472-480	1.4	1
23	Ten years experience with belatacept-based immunosuppression after kidney transplantation. <i>Journal of Clinical Medicine Research</i> , 2014 , 6, 98-110	2.9	6
22	Belatacept: in adult kidney transplant recipients. <i>BioDrugs</i> , 2012 , 26, 413-24	7.9	2
21	Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016 , 20, 1-324	4.4	9
20	Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. <i>Health Technology Assessment</i> , 2016 , 20, 1-594	4.4	26
19	Modern Immunosuppressive Therapy in Kidney Transplantation. <i>Open Journal of Organ Transplant Surgery</i> , 2013 , 03, 22-31		5
18	Hypertension: The Neglected Complication of Transplantation. <i>ISRN Hypertension</i> , 2013 , 2013, 1-10		8
17	Immunology of Pediatric Renal Transplantation. 2015 , 1-51		
16	Immunology of Pediatric Renal Transplantation. 2016 , 2457-2500		
15	The Immunology of Pancreas Transplantation. 2016 , 265-269		
14	Hypertension in the Kidney Transplant Recipient. 2016 , 167-202		
13	Advantages of the Eye as a Target Organ for Cell-Based Therapy in the Central Nervous System. <i>Pancreatic Islet Biology</i> , 2019 , 1-10	0.4	
12	Primary Care of the Adult Kidney Transplant and Kidney-Pancreas Transplant Recipient. 2020 , 49-76		
11	Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1908-1914	4.5	1
10	Immunosuppressive Pharmacology. 2021 , 329-338		
9	Structure Prediction and Expression of Modified rCTLA4-Ig as a Blocker for B7 Molecules. <i>Iranian Journal of Pharmaceutical Research</i> , 2020 , 19, 329-348	1.1	
8	Efficacy and safety of immune checkpoint inhibitors and cytokine therapy in autoimmune diseases. 2022 , 205-242		
7	CD86 occupancy in belatacept-treated kidney transplant patients is not associated with clinical and infectious outcomes.. <i>American Journal of Transplantation</i> , 2022 ,	8.7	0

- 6 Induction Therapy and Therapeutic Antibodies.. *Handbook of Experimental Pharmacology*, **2022**, 3.2
- 5 Pharmacotherapeutic options for the prevention of kidney transplant rejection: the evidence to date. *Expert Opinion on Pharmacotherapy*, 4
- 4 Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion. 13, ○
- 3 Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial. **2023**, 9, e1449 ○
- 2 Screening and Management of PTLD. Publish Ahead of Print, ○
- 1 TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. **2023**, ○